Thông tin thuốc gốc
Chỉ định và Liều dùng
Adult: As immediate release tab: Initially, 1 mg daily at night. May increase to 2 mg daily after 3-4 wk, if necessary.
Child: ≥12 yr Same as adult dose.

ADHD (attention deficit hyperactivity disorder)
Child: 6-17 yr As extended-release tab: Initially, 1 mg once daily, increased if necessary by increments of not more than 1 mg per wk. Maintenance: 0.05-0.12 mg/kg daily, according to response and tolerability. Max: 6-12 yr 4 mg daily; 13-17 yr 7 mg daily.
Thận trọng
Patient w/ history of hypotension, heart block, bradycardia, CV disease, history of syncope or conditions which may predispose them to syncope (e.g. dehydration), history of QT prolongation, risk factors for torsade de pointes. Avoid abrupt withdrawal. Renal or hepatic impairment. Childn. Pregnancy and lactation.
Phản ứng phụ
Somnolence, bradycardia, hypotension, abdominal pain, dry mouth, dizziness, headache, constipation, depression, anxiety, fatigue, nausea, vomiting, diarrhoea, enuresis, impotence, orthostatic hypotension, decreased appetite, insomnia, nightmare, sedation, lethargy, irritability, rash.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, somnolence, and syncope, if affected, do not drive or operate machinery.
Monitor heart rate, BP and consider ECG prior to initiation.
Quá liều
Symptoms: Drowsiness, lethargy, bradycardia, resp depression, coma and hypotension. Management: Supportive treatment. Perform gastric lavage if ingestion is recent. Admin of activated charcoal may be considered.
Tương tác
Additive effect w/ diuretics, other antihypertensives, CNS depressants. Phenobarbital and phenytoin may decrease elimination half-life and plasma concentration of guanfacine for renally impaired patients. Additive sedative effect w/ centrally active depressants (e.g. phenothiazines, barbiturates, benzodiazepines). Increased plasma concentrations w/ CYP3A4/5 inhibitors (e.g. ketoconazole). Decreased rate and extent of exposure w/ CYP3A4 inducers (e.g. rifampicin).
Food Interaction
Avoid high-fat meal due to increased exposure (extended-release). Increased plasma concentrations w/ grapefruit juice. Additive sedative effect w/ alcohol.
Tác dụng
Description: Guanfacine is a selective α2A-adrenoceptor agonist that reduces sympathetic nerve impulse from the vasomotor centre to the heart and blood vessels, resulting in a decrease in peripheral vascular resistance, BP and heart rate.
Duration: Antihypertensive effect: 24 hr.
Absorption: Rapidly absorbed. Bioavailability: Approx 80%. Time to peak plasma concentration: 1-4 hr.
Distribution: Extensively distributed in tissues. Plasma protein binding: Approx 70%.
Metabolism: Metabolised rapidly in the liver via CYP3A4/5-mediated oxidation, w/ subsequent sulfation and glucuronidation.
Excretion: Via urine, as unchanged drug (approx 50%) and metabolites. Elimination half-life: 10-30 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Guanfacine, CID=3519, (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25˚C.
Phân loại ATC
C02AC02 - guanfacine ; Belongs to the class of imidazoline receptor agonists, centrally-acting antiadrenergic agents. Used in the treatment of hypertension.
Anon. Guanfacine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 27/05/2016.

Buckingham R (ed). Guanfacine hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 27/05/2016.

Guanfacine Hydrochloride Tablet (Mylan Pharmaceuticals Inc. DailyMed. Source: U.S. National Library of Medicine. Accessed 27/05/2016.

Guanfacine Tablet, Extended Release (AvKARE, Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 27/05/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Guanfacine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 27/05/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Guanfacine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in